Selecta Biosciences is a clinical-stage biopharmaceutical company that develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its lead therapeutic gene therapy program is SEL-302, and it is also developing biologic therapies and gene therapies for various diseases. The company has license and collaboration agreements with several pharmaceutical companies and is headquartered in Watertown, Massachusetts.